Glycominds
About:
Glycominds develops and commercializes autoimmune and chronic inflammatory disease management tools focused on multiple sclerosis.
Website: http://www.glycominds.com
Top Investors: BRM Capital, Millennium II Materials Technology Fund
Description:
Glycominds, a molecular diagnostics company, develops and commercializes autoimmune and chronic inflammatory disease management tools and services with a distinctive focus on the Multiple Sclerosis market. Their proprietary tests allow physicians to help identify patients at a higher risk for more severe disease outcomes.
Total Funding Amount:
$1M
Estimated Revenue Range:
Less than $1M
Headquarters Location:
Lod, HaMerkaz, Israel
Founded Date:
1999-01-01
Founders:
Number of Employees:
11-50
Last Funding Date:
2005-01-01
IPO Status:
Private
Industries:
© 2025 bioDAO.ai